Navana Pharmaceuticals PLC announcements
122 Dhaka Stock Exchange announcements for Navana Pharmaceuticals PLC (NAVANAPHAR) since 2022: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (17).
- NAVANAPHARM: Dividend Declaration
(cont. news of NAVANAPHARM): Reasons for stock dividend recommendation: Bonus shares have been recommended with a view to utilize them for business expansion. Bonus shares declared out of accumulated profit. Bonus share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the company or through reducing paid up capital or through doing anything so that the post dividend retained earnings become negative or debit balance. (end) The Board of Directors has recommended 6% Cash Dividend and 8% Stock Dividend i.e. 14% Dividend only for the year ended June 30, 2026. Date of AGM: 20.12.2026, Time: 10:00 A.M., Venue & Mode: To be communicated in due course. Record Date: 24.11.2026. The Company has also reported EPS of Tk. 5.93, NAV per share of Tk. 51.06 and NOCFPS of Tk. 18.59 for the year ended June 30, 2026 as against Tk. 4.54, Tk. 45.29 and Tk. 16.90 respectively for the year ended June 30, 2025. (cont.)
The first part of this announcement is missing from the archive. - NAVANAPHARM: Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2026) following its corporate declaration.
- Reschedule of Board Meeting under LR 19(1)
The Company has further informed that due to unavoidable circumstances, the meeting of the Board of Directors of the Company as per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on October 28, 2026 at 3:30 PM instead of earlier declared on October 15, 2026 to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 15, 2026 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
- Completion of share transfer outside the trading system
The company has informed that the transfer of 16,04,603 shares of Navana Pharmaceuticals PLC held by Mr. Manzurul Islam (Sponsor), transferor, to Dr. Md. Jonaid Shafiq (Managing Director), transferee, has been completed outside the trading system of the Exchange other than by way of gift as per declaration disseminated on 04.08.2026.
- Current Board Member status of the company.
(cont. news of NAVANAPHAR): Mrs. Saiqa Mazed-Chairman and Independent Director, Professor Dr. Md. Jonaid Shafiq-Managing Director, Dr. Sayeed Ahmed-Director, Mr. Javed Kaiser Ally-Director, Mrs. Tarana Ahmed-Director, Mrs. Masuma Parvin-Director, Mr. Khondaker Sabbir Mohammad Kabir (Nominee of Stratus Holdings Limited)-Director, Mr. Mohammad Arife Billah (Bar-At-Law)-Independent Director, Professor Mohammad Shofiqul Islam-Independent Director. (end) The company has informed that pursuant to the direction of the Bangladesh Securities and Exchange Commission reference no: BSEC/ICSD/SRIC/2026-313/part-03/123: dated June 18, 2026, the 64th Meetings of the Board of Directors of Navana Pharmaceuticals PLC. have been postponed, with a direction to maintain the composition of the Board as it stood at the 63rd Board Meeting. Accordingly, as per the 63rd Board Meeting, the current members of the Board of Directors are as follows: (cont.)
The first part of this announcement is missing from the archive. - Transfer of shares outside the Trading System of the Exchange
Dhaka Stock Exchange PLC. (DSE) has approved the transfer of 16,04,603 shares of Navana Pharmaceuticals PLC held by Mr. Manzurul Islam (Sponsor), transferor, to Dr. Md. Jonaid Shafiq (Managing Director), transferee, within next 30 working days with effect from August 02, 2026 outside the trading system of the Exchange other than by way of gift under Regulation 47(1)(b) of the Dhaka Stock Exchange (Listing) Regulations, 2015 as well as other applicable laws.
- Q3 Financials and decision to proceed with a Foreign Loan
(Q3 Un-audited): EPS was Tk. 1.22 for Jan-March 2026 as against Tk. 1.01 for Jan-March 2025; EPS was Tk. 4.59 for July 2025-March 2026 as against Tk. 3.49 for July 2024-March 2025. Diluted EPS was Tk. 1.20 for Jan-March 2026 and Diluted EPS was Tk. 4.55 for July 2025-March 2026. NOCFPS was Tk. 15.44 for July 2025-March 2026 as against Tk. 10.22 for July 2024-March 2025. NAV per share was Tk. 49.53 as on March 31, 2026 and Tk. 45.29 as on June 30, 2025. (cont.1) (Cont. news of NAVANAPHAR): 2. The Company has decided to proceed with a Foreign Loan Facilities for EUR 26,610,000.00 for 12 years from AKA Ausfuhrkredit-Gesellschaft mbH, Frankfurt, Germany, the sole arranger of which is KGMC Financial Service, Bangladesh. The Company has decided to avail the aforesaid facilities for expansion of its production facilities. The proposed financing shall remain subject to final approval from the concerned regulatory authorities & completion of due diligence. (end) (Cont. news of NAVANAPHAR): Reasons for significant deviation in EPS and NOCFPS: Increment of Earnings per Share in the reporting period by 31.52% because of growth of Sales Revenue as well as optimum cost management policy & Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 15.44 from Tk. 10.22, due to cash received from the customers was higher than the cash payment for operation in the reporting period. (cont.2)
- Continuation of Company Secretary
The Company has informed that Mr. Lorens Shamol Mollick, FCS continues to legally hold his position as the official Company Secretary of Navana Pharmaceuticals PLC.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on June 03, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): Diluted EPS was Tk. 1.65 for October-December 2025 as against Tk. 1.00 for October-December 2024; Diluted EPS was Tk. 3.35 for July-December 2025 as against Tk. 2.25 for July-December 2024. NOCFPS was Tk. 8.11 for July-December 2025 as against Tk. 3.16 for July-December 2024. NAV per share was Tk. 48.32 as on December 31, 2025 and Tk. 45.29 as on June 30, 2025. (cont.) (Cont. News of NAVANAPHAR): Reasons for deviation: EPS: Net Profit after Tax has increased due to the increment of Net Sales and Gross Profit as well as reduction of finance cost, as a result half yearly EPS increased by 50.22% from the previous year. NOCFPS: Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 8.11 from Tk. 3.16, because of cash received from the customers was higher than the cash payment to the vendors and others in the reporting period. (end)
- Board approves production project & liaison office in Sri Lanka
The company has informed that the Board of Directors in its meeting held on January 28, 2026, has approved, among others, the following agenda: 1. Approved the generic production project in factory and 2. Approved to establish a subsidiary/liaison office in Sri Lanka.
- Election of Chairman
The company has informed that the Board of Directors has elected Mr. Javed Kaiser Ally as the Chairman of the Board of the Company with immediate effect.
- Appointment of Managing Director
The Company has informed that the Board of Directors has decided to appoint Dr. Sayeed Ahmed as the Managing Director of the company with immediate effect.
- Appointment of Company Secretary (Acting)
The Company has informed that the Board of Directors has decided to appoint Mr. Md. Aminul Hoque Bhuiyan, ACS as the Acting Company Secretary of the company with immediate effect.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.